Oncology Research Review, Issue 39

In this issue:

Scoring clinical benefits of cancer drugs in GEP-NET
International variation in NET follow-up practices
Guidelines for follow-up of completely resected GEP-NETs
I-131 mIBG beneficial in metastatic pulmonary or GEP-NETs
Elevated NLR: an adverse prognostic factor for GEP-NETs?
Octreotide may improve survival in GEPNETs
SSA plus PRRT therapy: a survival benefit in GEP-NETs?
Survival after liver surgery/RFA for metastatic GEP-NETs
US-based management of metastatic GEP-NETs
Toxicity management in GEP-NETs

Please login below to download this issue (PDF)

Subscribe